(Q40822250)

English

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

scientific article published on February 1999

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

author name string

J T Brouwer

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

H G Niesters

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

S W Schalm

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

1 February 1999

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Journal of Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

192-198

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A French consensus conference on hepatitis C: screening and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring hepatitis C viremia in clinical samples: Can we trust the assays?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

International collaborative study on the second EUROHEP HCV-RNA reference panel

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980061-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(99)80061-0

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40822250&oldid=1540652483"